A systematic review and meta-analysis of the efficacy and adverse events of infliximab in comparison to corticosteroids and placebo in active ulcerative colitis

International Journal of Pharmacology

Volumn 7, Issue 3, 2011, Pages 325-332

  Nikfar, Shekoufeh ^a,b   Ehteshami Afshar, Solmaz ^c,d   Abdollahi, Mohammad ^a,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse events; Clinical remission; Clinical response; Corticoseteriod; Infliximab; Meta analysis; Serious adverse events; Systematic rewiew; Tumour necrosis factor; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; PLACEBO;

CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 79957801004     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2011.325.332     Document Type: Review

References (41)

1. Armuzzi, A., B. De Pascalis, A. Lupascu, P. Fedeli and D. Leo et al., 2004. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci., 8: 231-233.
2. Baghaei, A., H. Esmaily, A.H. Abdolghaffari, M. Baeeri, F. Gharibdoost and M. Abdollahi, 2010. Efficacy of Setarud (IMod), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamefhasone and infliximab. Indian J. Biochem. Biophys., 47: 219-226.
3. Bennejo, F., A. Lopez-Sanroman, J. Hinojosa, L. Castro, C. lurado and A.B. Gomez-Beldal, 2004. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev. Esp. Enferm. Dig., 96: 94-101.
4. Caviglia, R., M. Ribolsi, M. Rizzi, S. Emerenziani, M.L. Annunziata and M. Cicala, 2007. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J. Gastroenterol., 13: 5238-5244.
5. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials. Dig. Dis. Sci., 53: 1278-1284.
6. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2009. Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials. Central Eur. J. Med., 4: 164-170.
7. Esmaily, H., A. Vaziri-Bami, A.E. Miroliaee, M. Baeeri and M. Abdollahi, 2010. The correlation between NF-kB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam. Clin. Pharmacol. 10.1111/j.1472-8206. 2010.00893.x
8. Ferrante, M., S. Vermeire, K.H. Katsanos, M. Noman and G. Van Assche et al., 2007. Predictors of early response to in? Iximab in patients with ulcerative colitis. Inflamm. Bowel Dis., 13: 123-128.
9. Fidder, H., F. Schnitzler, M. Ferrante, M. Noman and K. Katsanos et al., 2009. long-term safety of infliximab for the treatment of inflammatory bowel disease: A single center cohort study. Gut, 58: 501-508.
10. Gavalas, E., J. Kountouras, C. Stergiopoulos, C. Zavos and D. Gisakis et al., 2007. Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology, 54: 1074-1079.
11. Gies, N, K.I. Kroeker, K. Wong and R.N. Fedorak, 2010. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment. Pharmacol. Ther., 32: 522-528.
12. Gornet, I.M., S. Couve, Z. Hassani, I.C. Delchier and P. Marteau et al., 2003. Infliximab for refractory ulcerative colitis or indeterminate colitis: An open-label multicentre study. Aliment. Pharmacol. Ther., 18: 175-181.
13. Hasani-Ranjbar, S., B. Larijani and M. Abdollahi, 2009. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm. Allergy Drug Targets, 8: 2-10.
14. Hosseini-Tabatabaei, A. and M. Abdollahi, 2008. Potassium channel openers and improvement of toxic stress: Do they have role in the management of inflammatory bowel disease. Inflamm. Allergy Drug Targets, 7: 129-135.
15. ladad, A.R. and M.W. Enkm, 2007. Randomized Controlled Trials: Questions, Answers and Musings. 2nd Edn., BMII Books, London.
16. lahanshahi, G., V. Motavasel, A. Rezaie, A.A. Hashtroudi, N.E. Daryani and M. Abdollahi, 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci., 49: 1752-1757.
17. larnerot, G., E. Hertervig, I. Friis-Liby, L. Blomquist and P. Karlen et al., 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology, 128: 1805-1811.
18. Miroliaee, A.E., H. Esmaily, A. Vaziri-Bami, M. Baeeri, A.R. Shahverdi and M. Abdollahi, 2011. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol. Mech. Methods, 21: 200-208.
19. Nakhai, L., A. Mohammadirad, N. Yasa, B. Minaie and S. Nikfar et al., 2007. Benefits of Zataria multiflora boiss in experimental model of mouse inflammatory bowel disease. eCAM., 4: 43-50.
20. Nikfar, S., H. Mirfazaelian and M. Abdollahi, 2010a. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: A systematic review and meta-analysis of placebo-controlled trials. Curr. Pharm. Des., 16: 3684-3698.
21. Nikfar, S., M. Darvish-Damavandi and M. Abdollahi, 2010b. A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis. Int. I. Pharmacol., 6: 826-835.
22. Nikfar, S., R. Rahimi, A. Rezaie and M. Abdollahi, 2009. A Meta-Analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig. Dis. Sci., 54: 1157-1170.
23. Ochsenkuhn, T., M. Sackmann and B. Goke, 2004. Infliximab for acute, not steroid-refractory ulcerative colitis: A randomized pilot study. Eur. I. Gastroenterol. Hepatol., 16: 1167-1171.
24. Probert, C.S., S.D. Hearing, S. Schreiber, T. Kuhbacher, S. Ghosh, ID. Arnottand, A. Forbes, 2003. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut, 52: 998-1002.
25. Rahimi, R., S. Nikfar, A. Rezaie and M. Abdollahi, 2006. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease. Clin. Ther., 28: 1983-1988.
26. Rahimi, R., S. Nikfar and M. Abdollahi, 2007a. Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids. Med. Sci. Monit, 13: 13-18.
27. Rahimi, R., S. Nikfar and M. Abdollahi, 2007b. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother., 61: 75-80.
28. Rahimi, R, S. Nikfar, A. Rezaie and M. Abdollahi, 2007c. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci., 52: 2920-2925.
29. Rahimi, R, S. Nikfar, F. Rahimi, B. Elahi, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008a. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci., 53: 2524-2531.
30. Rahimi, R, S. Nikfar, A. Rezaie and M. Abdollahi, 2008b. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis. Reprod. Toxicol., 25: 271-275.
31. Rahimi, R., S. Nikfar and A. Rezaie, 2008c. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. Arch. Med. Sci., 4: 185-190.
32. Rahimi, R, S. Nikfar, A. Rezaie and M. Abdollahi, 2009a. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: A meta-analysis. Dig. Dis. Sci., 54: 712-721.
33. Rahimi, R., S. Mozaffan, M. Abdollahi, 2009b. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig. Dis. Sci., 54: 471-480.
34. Rahimi, R., M.R. Shams-Ardekam and M. Abdollahi, 2010. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World I. Gastroenterol, 16: 4504-4514.
35. Regueiro, M., I. Curtis and S. Plevy, 2006. Infliximab for hospitalized patients with severe ulcerative colitis. I. Clin. Gastroenterol., 40: 476-481.
36. Reinisch, W., W.I. Sandborn, M. Bala, S. Yan and B.G. Feagan et al., 2007. Response and remission are associated with improved quality of life, employment and disability status, hours worked and productivity of patients with ulcerative colitis. Inflamm. Bowel Dis., 13: 1135-1140.
37. Rezaie, A., R.D. Parker and M. Abdollahi, 2007. Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause. Dig. Dis. Sci., 52: 2015-2021.
38. Rutgeerts, P., W.I. Sandborn, B.G. Feagan, W. Reinisch and A. Olson, et at, 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. I. Med., 353: 2462-2476.
39. Salari, P. and M. Abdollahi, 2009. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: Role of ATP. Rec. Pat. Endoc. Metab. Immune Drug Disc, 3: 69-75.
40. Salari-Sharif, P. and M. Abdollahi, 2010. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: A comprehensive review. Curr. Pharm. Des., 16: 3661-3667.
41. Sands, B.E., W.I. Tremaine, W.I. Sandborn, P.I. Rutgeerts and S.B. Hanauer, et al., 2001. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm. Bowel Dis., 7: 83-88.